Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 8/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.41 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.41 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.41 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6832525 | 0.89 | TGFBR1 (0.54) | TGFBR1GAAMAPTHTTKMT2A | |
| SCHEMBL6832462 | 0.89 | KDM4E (0.44) | TGFBR1MAPTKMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL6832965 | 0.89 | KCNN1 (0.44) | TGFBR1GAAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL6832044 | 0.89 | NR4A1 (0.43) | TGFBR1KMT2AMEN1MAPK10 | |
| SCHEMBL6832969 | 0.87 | GRM4 (0.42) | TGFBR1MAPTKMT2AMEN1KCNN1 | |
| SCHEMBL6834671 | 0.86 | PTGS2 (0.47) | TGFBR1 | |
| SCHEMBL6834641 | 0.86 | NPY5R (0.46) | TGFBR1KMT2AMAPK10 | |
| SCHEMBL6834538 | 0.85 | TGFBR1 (0.47) | TGFBR1HTTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL6180369 | 0.83 | TGFBR1 (0.59) | TGFBR1KMT2AMEN1 | |
| SCHEMBL6834633 | 0.81 | TGFBR1 (0.44) | TGFBR1KMT2AMEN1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097502-A1 | Pyrazoles as tgf inhibitors | GELLIBERT FRANCOISE JEANNE (FR) | 2004-05-20 | — | — | US | claimed |
| EP-1363904-A1 | PYRAZOLES AS TGF INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | claimed |
| WO-2002062787-A1 | PYRAZOLES AS TGF INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | claimed |
| US-20040097502-A1 | Pyrazoles as tgf inhibitors | GELLIBERT FRANCOISE JEANNE (FR) | 2004-05-20 | — | — | US | disclosed |
| EP-1363904-A1 | PYRAZOLES AS TGF INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002062787-A1 | PYRAZOLES AS TGF INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097502-A1 | Pyrazoles as tgf inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885GAA 2559/4885MAPT 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.